A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age60+
SponsorJinzhou Medical University
About this trial
Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. This study is to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.
Eligibility criteria
Qualifiers
Male patients aged ≥60 years.
ECOG performance status score of 0 ~1.
Expected survival time of more than 3 months.
Histologically or cytologically diagnosed advanced lung cancer according to the TNM staging system established by AJCC.
Disqualifiers
Exclusion of cases that do not meet the inclusion criteria
Trial design
Treatments tested in this trial
- Leuprorelin acetate + Sintilimab
- Sintilimab
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Jinzhou Medical University
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Collaborator
Source ClinicalTrials.gov